Esketamine Nasal Spray Beneficial for Treatment-Resistant Depression
THURSDAY, Oct. 5, 2023 (HealthDay News) — For patients with treatment-resistant depression, esketamine nasal spray is superior to extended-release quetiapine with respect to remission at week 8, according to a study published in the Oct. 5 issue of t…
Learn MoreSarilumab Beneficial for Polymyalgia Rheumatica Patients
THURSDAY, Oct. 5, 2023 (HealthDay News) — For patients with polymyalgia rheumatica with relapse during tapering of glucocorticoid therapy, treatment with sarilumab, the human monoclonal antibody that binds to the interleukin-6 receptor α, is efficaci…
Learn MoreSarilumab Beneficial for Polymyalgia Rheumatica Patients
THURSDAY, Oct. 5, 2023 (HealthDay News) — For patients with polymyalgia rheumatica with relapse during tapering of glucocorticoid therapy, treatment with sarilumab, the human monoclonal antibody that binds to the interleukin-6 receptor α, is efficaci…
Learn MoreEarly Metformin May Not Aid Gestational Diabetes
THURSDAY, Oct. 5, 2023 (HealthDay News) — Early metformin initiation in women with gestational diabetes does not reduce the occurrence of the combination of a fasting glucose level ≥5.1 mmol/L at gestation weeks 32 or 38 or insulin initiation, accord…
Learn MoreEarly Metformin May Not Aid Gestational Diabetes
THURSDAY, Oct. 5, 2023 (HealthDay News) — Early metformin initiation in women with gestational diabetes does not reduce the occurrence of the combination of a fasting glucose level ≥5.1 mmol/L at gestation weeks 32 or 38 or insulin initiation, accord…
Learn MoreTirzepatide Bests Semaglutide for Patients With Type 2 Diabetes
THURSDAY, Oct. 5, 2023 (HealthDay News) — Tirzepatide is superior to semaglutide for both blood sugar control and weight loss among people with type 2 diabetes, according to research presented at the European Association for the Study of Diabetes Ann…
Learn MoreTirzepatide Bests Semaglutide for Patients With Type 2 Diabetes
THURSDAY, Oct. 5, 2023 (HealthDay News) — Tirzepatide is superior to semaglutide for both blood sugar control and weight loss among people with type 2 diabetes, according to research presented at the European Association for the Study of Diabetes Ann…
Learn MoreCancer Drug Shortages Persist Across U.S.
THURSDAY, Oct. 5, 2023 (HealthDay News) — U.S. cancer centers continue to have shortages of commonly used chemotherapy drugs, a new survey shows, though the medications are not as scarce as they were last June.The National Comprehensive Cancer Networ…
Learn MoreDurable Reductions in HbA1c, Body Weight Seen With Semaglutide
WEDNESDAY, Oct. 4, 2023 (HealthDay News) — Use of once-weekly subcutaneous semaglutide is associated with sustained reductions in hemoglobin A1c (HbA1c) and body weight, according to a study presented at the annual meeting of the European Association…
Learn MoreNirmatrelvir/Ritonavir Cuts COVID-19 Complications in Highest-Risk Patients
WEDNESDAY, Oct. 4, 2023 (HealthDay News) — For individuals with the highest risk for complications from COVID-19 infection, nirmatrelvir and ritonavir is associated with a reduced risk for COVID-19 hospitalization or death, according to a study publi…
Learn More